Siegfried Holding AG
SFZN
Hisse Senetlerindeki Sıralama
#4106
Siegfried Holding AG, together with its subsidiaries, engages in contract... Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs. The company also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition. In addition, it offers drug products, including steriles, which includes fill and finish in vials, ampoules, cartridges, and pre-filled syringes; ophthalmics, such as sterile ointments, gels, and suspensions and solutions; inhalation products, including capsules in medical devices for inhalation applications; oral solid dosage forms, which includes tablets and capsules; and viral vectors, such as AAV and lentiviruses for gene therapy. Further, the company provides technologies with chemistry capabilities, analytical services, formulation technologies, bridging technologies, containment technology, and cell and gene therapies. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.
Hisse Fiyatı
$88.34
Piyasa Değeri
$3.87B
Değişim (1 gün)
1.68%
Değişim (1 yıl)
-12.97%
Ülke
CH
Ticaret Siegfried Holding AG (SFZN)
Kategori
Healthcare
Siegfried Holding AG (SFZN) için kazanç
2026 itibarıyla kazanç TTM: 0
Siegfried Holding AG şirketinin en son finansal raporlarına göre, mevcut kazancı 0'dir. 2026 yılında şirket 0 kazanç elde etti, bu 2026 yılındaki 0 kazanca göre önceki yıla eşit. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Siegfried Holding AG için kazanç geçmişi 2002 - 2026
Her yılın sonundaki kazanç
| Yıl | Kazanç | Değiştir |
|---|---|---|
| 2025 | $262.95M | 21.02% |
| 2024 | $217.28M | 21.51% |
| 2023 | $178.81M | -24.44% |
| 2022 | $236.63M | 70.46% |
| 2021 | $138.82M | 68.39% |
| 2020 | $82.44M | 54.98% |
| 2019 | $53.19M | -25.42% |
| 2018 | $71.32M | 20.14% |
| 2017 | $59.37M | 73.97% |
| 2016 | $34.13M | -7.94% |
| 2015 | $37.07M | 15.84% |
| 2014 | $32.00M | -43.19% |
| 2013 | $56.32M | 239.87% |
| 2012 | $16.57M | 48.10% |
| 2011 | $11.19M | -312.32% |
| 2010 | $-5.27M | -86.49% |
| 2009 | $-39.02M | -52.71% |
| 2008 | $-82.51M | -453.96% |
| 2007 | $23.31M | 6.35% |
| 2006 | $21.92M | -32.38% |
| 2005 | $32.41M | 96.31% |
| 2004 | $16.51M | -65.51% |
| 2003 | $47.87M | -4.28% |
| 2002 | $50.01M | 0.00% |
Benzer şirketler veya rakipler için kazanç
| Şirket | Kazanç | Kazanç Farkı | Ülke |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | - |
IN
|
